JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Increased Expression and Prognostic Significance of BYSL in Melanoma

  • 0Department of Dermatology, School of Medicine, Shanghai Fourth People's Hospital, Tongji University, Shanghai, China.
Journal of Immunotherapy +

|

July 9, 2024

|

July 9, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

BYSL expression in melanoma (SKCM) correlates with tumor grade and patient survival. Its regulation involves methylation and microRNAs, suggesting BYSL as a prognostic biomarker and potential factor in immune cell invasion.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Melanoma (SKCM) poses significant challenges in patient prognosis and treatment.
  • Understanding the molecular mechanisms and biomarkers for SKCM is crucial for improving patient outcomes.

Purpose Of The Study

  • To investigate the role of BYSL expression in melanoma (SKCM) and its association with overall survival (OS).
  • To explore the underlying regulatory mechanisms, including methylation and microRNA interactions, of BYSL in SKCM.
  • To assess the potential of BYSL as a prognostic biomarker and its immunologic significance in melanoma.

Main Methods

  • Utilized a comprehensive bioinformatics approach including miRNA estimation, quantitative real-time polymerase chain reaction (qRT-PCR), E3 ligase estimation, STRING and TIMER analyses.
  • Performed protein-protein interaction (PPI) analysis, upstream modulator examination, and retrospective/survival analyses.
  • Validated findings using clinical SKCM samples and sera.

Main Results

  • BYSL expression is negatively regulated by BYSL methylation and associated with higher tumor grade in 468 SKCM samples.
  • Identified five key microRNAs (hsa-miR-146b-3p, hsa-miR-342-3p, hsa-miR-511-5p, hsa-miR-3690, hsa-miR-193a-5p) strongly associated with BYSL levels.
  • Predicted E3 ubiquitin ligases (CBL, FBXW7, FZR1, KLHL3, MARCH1) and interacting proteins (PNO1, RIOK2, TSR1, WDR3, NOB1) modulating BYSL, and found a correlation with dendritic cells (DCs).

Conclusions

  • BYSL serves as a robust bioindicator for predicting SKCM patient prognosis.
  • BYSL expression is linked to tumor progression and may influence immune cell invasion in melanoma.
  • BYSL's regulation by methylation and microRNAs offers potential therapeutic targets.